Unable to find a retooled deal pleasing to both sides, ImmunoGen Inc. and GlaxoSmithKline plc - which earlier said they were striving to do so - have ended their development agreement for cantuzumab mertansine (huC242-DM1). (BioWorld Today) Read More
